Opus Genetics (IRD) said Friday that it has priced a $20 million underwritten public offering, as well as a concurrent private placement for gross proceeds of $1.5 million.

The ophthalmic biotechnology company said there will also be up to $21.4 million in additional proceeds when the warrants are exercised. The offerings are expected to close Monday.

Opus said the net proceeds will be used to fund the clinical development of its lead gene therapy programs, OPGx-LCA5 and OPGx-BEST1, as well as general corporate purposes and working capital.